Diminazene aceturate experimental repeat treatments in albino rats: efficacy and clinico-pathologic considerations
- 18 Downloads
To determine the clinico-pathologic effects, safety and efficacy of diminazene aceturate repeat treatments, thirty adult albino rats were randomly assigned into six groups (A–F) of five rats each. Groups A–D were infected with 1.0 × 106 trypanosomes, while groups E and F served as uninfected controls. Groups A–E were treated once with 7 mg/kg Dinazene® on day 11 post-infection. Treatments were repeated once, twice and thrice in groups B–D respectively at 7 days interval. The serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, blood urea nitrogen, creatinine and conjugated bilirubin were assayed bi-weekly. Parasitaemia level was also monitored. An average pre-patent period of 7 days was recorded. Relapse infection was recorded on days 24, 31 and 24 following first, second and third treatments for groups A, B and C respectively. The serum levels of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, conjugated bilirubin and creatinine of the infected and repeatedly treated groups did not differ significantly from those of the control groups except for the groups in which relapse infection occurred. It was concluded that repeat treatments using 7 mg/kg diminazene aceturate was safe and protected against relapse after the fourth consecutive treatments.
KeywordsRepeat treatments Serum enzymes Diminazene aceturate Trypanosomosis Rats
IOE and RCE designed the study. NEU, VOE, CFO, MIO, CNI and IOE carried out the laboratory experiment. IOE performed the statistical analysis, while NEU, CFO and IOE drafted the manuscript. All authors read, critically revised the manuscript for intellectual content and approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Valid approval and ethical clearance were obtained from the Ethics Committee for Medical and Scientific Research of the University of Nigeria, Nsukka before the commencement of this study. Also, all applicable international, national and/or institutional guidelines for the care and use of animals were followed.
- Ezeh IO, Agbo LI, Emehelu CO, Nweze EN, Ezeokonkwo RC, Onah DN (2009) Berenil-resistant Trypanosoma brucei brucei infection in a hunting dog in Nsukka area, Enugu state, Nigeria. Niger Vet J 29:34–42Google Scholar
- Ezeokonkwo RC, Okoro FC, Ezeh IO (2007) The efficacy of increasing doses of Samorenil® in the treatment of Trypanosoma brucei infected albino rats. Niger Vet J 28:24–32Google Scholar
- Holmes PH, Eisler MC, Geerts S (2004) Current chemotherapy of animal trypanosomiasis. In: Maudin I, Holmes PH, Miles MA (eds) The trypanosomiasis. CAB International, Wallingford, pp 369–402Google Scholar
- Knoll JS (1998) Collection and submission of laboratory samples, diagnostic procedures for the private practice laboratory. In: Aijello S (ed) The Merck veterinary manual. Merck and Co Inc., New JerseyGoogle Scholar
- Shiferaw S, Muktar Y, Belina D (2015) A review on trypanocidal drug resistance in Ethiopia. J Parasitol Vector Biol 7:58–66Google Scholar
- Teko-Agbo A, Ndjana FM, Walbadet L, Akoda K, Niang EH, Abiola FA (2008) Quality of veterinary medicinal products in circulation in Cameron and Senegal. OIE Conference on Veterinary Medicinal Products in Africa, DakarGoogle Scholar